EU/3/15/1594

About

On 14 December 2015, orphan designation (EU/3/15/1594) was granted by the European Commission to Medpace Germany GmbH, Germany, for live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin for treatment of malignant mesothelioma.

The sponsorship was transferred to Aduro Biotech Holdings, Europe B.V., The Netherlands, in April 2016.

Key facts

Active substance
Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin
Disease / condition
Treatment of malignant mesothelioma
Date of decision
14/12/2015
Outcome
Positive
Orphan decision number
EU/3/15/1594

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Aduro Biotech Holdings, Europe B.V.
Pivot Park RX 1101
Molenweg 79
5349 AC Oss
The Netherlands
Tel. +31 8 80 12 14 00
Fax +31 2 07 11 81 40

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating